CLINICAL_TRIALS
trial_result
· 2019-05-01
Clinical Trial Update: A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
Summary
A Phase II study evaluating carfilzomib for relapsed or refractory mantle cell lymphoma has been terminated, with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-01